Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel enzymatic route for 4-AA intermediate reduces costs and improves purity for penem antibiotic manufacturing supply chains globally.
Patent CN103122355A details a thermostable ketoreductase enabling high-purity chiral alcohol manufacturing with significant cost reduction and supply chain reliability.
Patent CN109837317B details a novel enzymatic method for synthesizing high-purity chiral alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN102102087B details a novel Leifsonia xyli strain for producing key Aprepitant intermediates with superior yield and optical purity, offering significant supply chain advantages.
Patent CN104328147A details a novel biocatalytic route for chiral esters offering high purity and scalable manufacturing solutions for global supply chains.
Novel ruthenium catalyst method for ceramide intermediates. High stereoselectivity and reduced reaction time for supply chain efficiency.
Patent CN115011573B enables efficient synthesis of chiral alcohols with high substrate loading and reduced cofactor costs for pharmaceutical supply chains.
Patent CN104152506B reveals a crude enzyme system for high-purity pharmaceutical intermediates. This method offers significant supply chain and cost advantages for global buyers.
Patent CN113387925B reveals a cost-effective S-nicotine synthesis using glutarate. Discover high-purity manufacturing solutions and supply chain advantages.
Patent CN104651425A enables high-purity lactone production with reduced costs and enhanced supply chain reliability for flavor manufacturers globally.
Patent CN102643879B reveals microbial route for duloxetine intermediate. High purity, scalable production offers significant supply chain and cost advantages.
Patent CN104650022A details a novel Nebivolol synthesis avoiding column chromatography. Enhance supply chain reliability and reduce API manufacturing costs with scalable routes.
Patent CN115109759A reveals engineered carbonyl reductases achieving 600g/g S/C ratio. Discover cost-effective biocatalytic routes for chiral alcohol production.
Patent CN111454918A details a novel OYE3-Mut mutant for >99% ee (R)-citronellal, offering cost-effective biocatalytic solutions for flavor and pharma intermediates.
Patent CN111100851B discloses high-efficiency TbSADH mutants for synthesizing chiral biaryl alcohols with >99% ee, offering a green alternative to metal catalysis.
Novel LsCR mutant enables efficient synthesis of chiral alcohols for anticoagulants. Enhanced stability and activity reduce manufacturing costs for pharmaceutical intermediates.
Patent CN112708641A discloses a high-efficiency chemo-enzymatic route for tomoxetine. Achieves >99.9% ee and high substrate loading for cost-effective manufacturing.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
This patent details a novel biocatalytic route for sitagliptin intermediates offering high purity and yield. It enables significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Patent CN102876734B details a novel carbonyl reductase for high-purity chiral alcohol production, offering significant cost and supply chain advantages for API intermediates.